EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions

Camille N Pierre, Lily E Adams, Jaclyn S Higgins, Kara Anasti, Derrick Goodman, Dieter Mielke, Sherry Stanfield-Oakley, John M Powers, Dapeng Li, Wes Rountree, Yunfei Wang, Robert J Edwards und 6 weitere

PLOS Pathogens · 2024

DOI: 10.1371/journal.ppat.1011569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Camille N Pierre und 17 weiteren Autor:innen. Beteiligte Einrichtung: Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral, Antibodies, Neutralizing. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibodies perform both neutralizing and non-neutralizing effector functions that protect against certain pathogen-induced diseases. A human antibody directed at the SARS-CoV-2 Spike N-terminal domain (NTD), DH1052, was recently shown to be non-neutralizing, yet it protected mice and cynomolgus macaques from severe disease. The mechanisms of NTD non-neutralizing antibody-mediated protection are unknown. Here we show that Fc effector functions mediate NTD non-neutralizing antibody (non-nAb) protection against SARS-CoV-2 MA10 viral challenge in mice. Though non-nAb prophylactic infusion did not suppress infectious viral titers in the lung as potently as neutralizing antibody (nAb) infusion, disease markers including gross lung discoloration were similar in nAb and non-nAb groups. Fc functional knockout substitutions abolished non-nAb protection and increased viral titers in the nAb group. Fc enhancement increased non-nAb protection relative to WT, supporting a positive association between Fc functionality and degree of protection from SARS-CoV-2 infection. For therapeutic administration of antibodies, non-nAb effector functions contributed to virus suppression and lessening of lung discoloration, but the presence of neutralization was required for optimal protection from disease. This study demonstrates that non-nAbs can utilize Fc-mediated mechanisms to lower viral load and prevent lung damage due to coronavirus infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Antibodies, ViralAntibodies, NeutralizingImmunoglobulin Fc FragmentsSpike Glycoprotein, CoronavirusAnimalsMiceHumansFemaleProtein DomainsViral LoadLung

Substanzen

Antibodies, ViralAntibodies, NeutralizingImmunoglobulin Fc FragmentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
  • Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Department of Surgery, Duke University School of Medicine, Durham, North Carolina, United States of America.
  • Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Kevin O Saunders

Förderung

  • NIAID NIH HHS
  • Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Zitieren

APA

Pierre, C. N., Adams, L. E., Higgins, J. S., Anasti, K., Goodman, D., Mielke, D., Stanfield-Oakley, S., Powers, J. M., Li, D., Rountree, W., Wang, Y., Edwards, R. J., Alam, S. M., Ferrari, G., Tomaras, G. D., Haynes, B. F., Baric, R. S., & Saunders, K. O. (2024). Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1011569

Vancouver

Pierre CN, Adams LE, Higgins JS, Anasti K, Goodman D, Mielke D, et al. Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1011569

BibTeX
@article{Pierre2024,
  author = {Pierre, Camille N and Adams, Lily E and Higgins, Jaclyn S and Anasti, Kara and Goodman, Derrick and Mielke, Dieter and Stanfield-Oakley, Sherry and Powers, John M and Li, Dapeng and Rountree, Wes and Wang, Yunfei and Edwards, Robert J and Alam, S Munir and Ferrari, Guido and Tomaras, Georgia D and Haynes, Barton F and Baric, Ralph S and Saunders, Kevin O},
  title = {Non-neutralizing SARS-CoV-2 N-terminal domain antibodies protect mice against severe disease using Fc-mediated effector functions},
  journal = {PLOS Pathogens},
  year = {2024},
  doi = {10.1371/journal.ppat.1011569}
}
Kostenlos starten →